Australia markets closed
  • ALL ORDS

    7,325.20
    +19.20 (+0.26%)
     
  • ASX 200

    7,080.80
    +19.10 (+0.27%)
     
  • AUD/USD

    0.7847
    +0.0062 (+0.80%)
     
  • OIL

    64.82
    +0.11 (+0.17%)
     
  • GOLD

    1,832.00
    +16.30 (+0.90%)
     
  • BTC-AUD

    73,477.01
    +1,381.03 (+1.92%)
     
  • CMC Crypto 200

    1,480.07
    +44.28 (+3.08%)
     
  • AUD/EUR

    0.6447
    -0.0002 (-0.02%)
     
  • AUD/NZD

    1.0769
    +0.0013 (+0.12%)
     
  • NZX 50

    12,729.92
    -21.75 (-0.17%)
     
  • NASDAQ

    13,719.63
    +105.90 (+0.78%)
     
  • FTSE

    7,129.71
    +53.54 (+0.76%)
     
  • Dow Jones

    34,777.76
    +229.23 (+0.66%)
     
  • DAX

    15,399.65
    +202.91 (+1.34%)
     
  • Hang Seng

    28,610.65
    -26.81 (-0.09%)
     
  • NIKKEI 225

    29,357.82
    +26.45 (+0.09%)
     

Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease

·1-min read

TOKYO, Apr 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Biogen (Nasdaq: BIIB) has disclosed, in its Q1 2021 Earnings Press Release issued on April 22, its current submission status of the Marketing Authorization Applications (MAA) for aducanumab, an investigational treatment for Alzheimer's disease, in countries other than the United States, Japan, and in Europe which have been announced previously.

In the first quarter of 2021 Biogen submitted a MAA to Ag?ncia Nacional de Vigil?ncia Sanit?ria (ANVISA) in Brazil for aducanumab an investigational treatment for Alzheimer's disease. This application is currently in queue for review.

Biogen also submitted MAAs for aducanumab to Health Canada, the Therapeutic Goods Agency in Australia, and Swissmedic in Switzerland, all of which are subject to agency validation of whether the applications are accepted.

Aducanumab is being jointly developed by Biogen and Eisai.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com